Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

138.68USD
22 Oct 2018
Change (% chg)

$-0.37 (-0.27%)
Prev Close
$139.05
Open
$138.86
Day's High
$139.25
Day's Low
$138.14
Volume
1,639,585
Avg. Vol
1,992,638
52-wk High
$148.32
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Janssen Submits New Drug Application To U.S. FDA Seeking Approval Of Erdafitinib For The Treatment Of Metastatic Urothelial Cancer
Tuesday, 18 Sep 2018 04:30pm EDT 

Sept 18 (Reuters) - Johnson & Johnson ::JANSSEN SUBMITS NEW DRUG APPLICATION TO U.S. FDA SEEKING APPROVAL OF ERDAFITINIB FOR THE TREATMENT OF METASTATIC UROTHELIAL CANCER.JANSSEN PHARMACEUTICAL - LOOK FORWARD TO WORKING WITH FDA IN AGENCY'S REVIEW OF APPLICATION.  Full Article

Janssen Announces Results From Mariner And Commander Hf Studies
Monday, 27 Aug 2018 05:19am EDT 

Aug 27 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES RESULTS FROM MARINER AND COMMANDER HF STUDIES.JANSSEN-IN MARINER & COMMANDER HF STUDIES,THERE WAS NO SIGNIFICANT DIFFERENCE FOUND BETWEEN XARELTO(RIVAROXABAN) & PLACEBO FOR PRIMARY EFFICACY ENDPOINTS.JANSSEN SAYS IN COMMANDER HF, XARELTO DID NOT IMPACT OVERALL MORTALITY OUTCOMES VERSUS STANDARD OF CARE.JANSSEN- IN MARINER STUDY, XARELTO DID SIGNIFICANTLY REDUCE VTE WITH CONSISTENT SAFETY, REINFORCING MEDICINE'S POSITIVE BENEFIT-RISK PROFILE.JANSSEN - MARINER SHOWED XARELTO DID NOT REDUCE COMPOSITE ENDPOINT OF VENOUS THROMBOEMBOLISM & VTE-RELATED DEATH.  Full Article

Janssen Submits U.S. & EU Regulatory Applications Seeking Approval Of Darzalex
Wednesday, 8 Aug 2018 07:30am EDT 

Aug 8 (Reuters) - Johnson & Johnson ::JANSSEN SUBMITS U.S. & EU REGULATORY APPLICATIONS SEEKING APPROVAL OF DARZALEX® (DARATUMUMAB) SPLIT DOSING REGIMEN.JANSSEN SAYS APPLICATIONS SEEK TO UPDATE CERTAIN PRODUCT CHARACTERISTICS TO GIVE PROFESSIONALS OPTION TO SPLIT FIRST INFUSION OF DARZALEX OVER 2 DAYS.  Full Article

Janssen's Tremfya Receives First Two Positive Assessments In Europe
Wednesday, 13 Jun 2018 09:07am EDT 

June 13 (Reuters) - Johnson & Johnson ::JANSSEN’S TREMFYA®▼ (GUSELKUMAB) RECEIVES ITS FIRST TWO POSITIVE HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE.JANSSEN PHARMACEUTICAL - UK'S NICE PUBLISHED POSITIVE GUIDANCE FOR TREMFYA, FOLLOWING POSITIVE FINAL APPRAISAL DETERMINATION DELIVERED ON 2 MAY.  Full Article

Fujirebio Says Entered Into Agreement With Janssen Pharmaceuticals
Thursday, 26 Apr 2018 07:30am EDT 

April 26 (Reuters) - Miraca Holdings Inc <4544.T>::FUJIREBIO SAYS ENTERED INTO AGREEMENT WITH JANSSEN PHARMACEUTICALS TO DEVELOP & COMMERCIALIZE AMYLOID Β 42/40 RATIO ASSAY.FUJIREBIO - ASSAY INTENDED TO IDENTIFY PATIENTS WHO MAY BENEFIT FROM TREATMENT WITH JANSSEN'S NEW INVESTIGATIONAL ORAL BACE INHIBITOR, ATABECESTAT.  Full Article

U.S. FDA Says Cleared Contact Lens To Incorporate Additive That Automatically Darkens Lens When Exposed To Bright Light
Tuesday, 10 Apr 2018 01:32pm EDT 

April 10 (Reuters) - U.S. Food & Drug Administration::U.S. FOOD & DRUG ADMINISTRATION SAYS CLEARED FIRST CONTACT LENS TO INCORPORATE ADDITIVE THAT AUTOMATICALLY DARKENS LENS WHEN EXPOSED TO BRIGHT LIGHT.U.S. FDA SAYS GRANTED CLEARANCE OF THE ACUVUE OASYS CONTACT LENSES WITH TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY TO JOHNSON & JOHNSON VISION CARE INC.  Full Article

Dominic Caruso To Retire As Chief Financial Officer Of Johnson & Johnson
Tuesday, 20 Mar 2018 04:15pm EDT 

March 20 (Reuters) - Johnson & Johnson ::DOMINIC J. CARUSO TO RETIRE AS CHIEF FINANCIAL OFFICER OF JOHNSON & JOHNSON.J&J - ‍DOMINIC J. CARUSO TO RETIRE AS CHIEF FINANCIAL OFFICER​.J&J - ‍JOSEPH WOLK PROMOTED TO EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER​.  Full Article

Janssen Announces FDA Breakthrough Therapy Designation For Erdafitinib In The Treatment Of Metastatic Urothelial Cancer
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ERDAFITINIB IN THE TREATMENT OF METASTATIC UROTHELIAL CANCER.JANSSEN PHARMACEUTICAL - BREAKTHROUGH THERAPY DESIGNATION BASED ON DATA FROM MULTICENTER, OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ERDAFITINIB.  Full Article

J&J Says CEO Alex Gorsky's FY 2017 Total Compensation Was $29.8 Mln Vs $26.9 Mln In FY 2016
Wednesday, 14 Mar 2018 08:25am EDT 

March 14 (Reuters) - Johnson & Johnson ::J&J SAYS CHAIRMAN AND CEO ALEX GORSKY'S FY 2017 TOTAL COMPENSATION WAS $29.8 MILLION VERSUS $26.9 MILLION IN FY 2016 - SEC FILING.J&J - CFO DOMINIC CARUSO'S TOTAL COMPENSATION FOR 2017 WAS $11.7 MILLION VERSUS $11.3 MILLION IN 2016.J&J - EVP, WORLDWIDE CHAIRMAN PHARMACEUTICALS JOAQUIN DUATO'S TOTAL COMPENSATION FOR 2017 WAS $19.4 MILLION VERSUS $10.1 MILLION IN 2016.  Full Article

Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs
Tuesday, 27 Feb 2018 08:00am EST 

Feb 27 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES.ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​.ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​.ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​.ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED.  Full Article

Deals of the day-Mergers and acquisitions

Oct 23 The following bids, mergers, acquisitions and disposals were reported by 10:00 GMT on Tuesday: